Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6220719 | 0.98 | GAA (0.52) | GAAALDH1A1HTTTDP1POLB | |
| SCHEMBL9979988 | 0.98 | GAA (0.52) | GAAALDH1A1HTTTDP1POLB | |
| SCHEMBL12233164 | 0.95 | — | — | |
| SCHEMBL19268642 | 0.90 | TDP1 (0.47) | GAAALDH1A1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL16076280 | 0.90 | TDP1 (0.47) | GAAALDH1A1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL23105019 | 0.85 | HSD17B10 (0.44) | GAAALDH1A1HTTTDP1POLB | |
| SCHEMBL17092622 | 0.84 | GAA (0.56) | GAAALDH1A1HTTTDP1POLB | |
| SCHEMBL10109058 | 0.83 | MEN1 (0.47) | GAAALDH1A1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL10892602 | 0.81 | GAA (0.54) | GAAALDH1A1HTTTDP1POLB | |
| SCHEMBL142180 | 0.81 | GAA (0.61) | GAAALDH1A1HTTTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691271-A2 | TOBACCO TREATMENT | British American Tobacco (Investments) Limited (GB) | 2026-02-11 | — | — | EP | claimed |
| EP-3560356-B1 | TOBACCO TREATMENT | BRITISH AMERICAN TOBACCO INVESTMENTS LTD (GB) | 2025-12-24 | — | — | EP | claimed |
| CN-109965339-B | Tobacco treatment | 英美烟草(投资)有限公司 | 2022-05-24 | — | — | CN | claimed |
| US-10966451-B2 | Tobacco treatment | BRITISH AMERICAN TOBACCO (INVESTMENTS) LIMITED (GB) | 2021-04-06 | — | — | US | claimed |
| EP-3560356-A1 | TOBACCO TREATMENT | British American Tobacco (Investments) Limited (GB) | 2019-10-30 | — | — | EP | claimed |
| EP-3062640-B1 | TOBACCO TREATMENT | BRITISH AMERICAN TOBACCO INVESTMENTS LTD (GB) | 2019-07-24 | — | — | EP | claimed |
| CN-109965339-A | Tobacco processing | 英美烟草(投资)有限公司 | 2019-07-05 | — | — | CN | claimed |
| US-20190174813-A1 | TOBACCO TREATMENT | BRITISH AMERICAN TABACCO PRESTADORA DE SERVICOS LTDA (BR) | 2019-06-13 | — | — | US | claimed |
| US-10264813-B2 | Tobacco treatment | BRITISH AMERICAN TOBACCO (INVESTMENTS) LIMITED (GB) | 2019-04-23 | — | — | US | claimed |
| CN-105848502-B | tobacco processing method | 英美烟草(投资)有限公司 | 2019-04-16 | — | — | CN | claimed |
| US-20160270435-A1 | TOBACCO TREATMENT | BRITISH AMERICAN TABACCO PRESTADORA DE SERVICOS LTDA (BR) | 2016-09-22 | — | — | US | claimed |
| CN-105848502-A | Tobacco treatment | 英美烟草(投资)有限公司 | 2016-08-10 | — | — | CN | claimed |
| JP-9140348-A | — | — | None | — | — | JP | disclosed |
| EP-4691271-A2 | TOBACCO TREATMENT | British American Tobacco (Investments) Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| EP-3560356-B1 | TOBACCO TREATMENT | BRITISH AMERICAN TOBACCO INVESTMENTS LTD (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4651738-A1 | TOBACCO TREATMENT | Nicoventures Trading Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010096462-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010091413-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| JP-H09140348-A | AGENT FOR IMPROVING FLAVOR AND SMELL QUALITY OF FOOD PERFUME AND IMPROVEMENT OF FLAVOR AND SMELL QUALITY OF FOOD PERFUME AND FOOD PERFUME COMPOSITION | SHIONO KORYO KK | 1997-06-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | GAA 433/4885ALDH1A1 287/4885HTT 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.